Integration of models and experimentation to optimise the production of potential biotherapeutics.

Despite decades of clinical and commercial success, the current paradigm for drug discovery and development is still empirical and costly. The many hundreds of therapeutic proteins (TPs) in the development pipeline and the FDA-led quality-by-design initiative represent opportunities to address this issue. Advances in our understanding of cellular mechanisms as well as the physicochemical and biological characteristics of TPs have enabled researchers to develop computational models that analyse or even predict molecular and cellular behaviour under different conditions. Coupled with new analytical tools, these models are increasingly used to systemise and expedite the design and optimisation of protein production processes throughout the discovery and development stages.

[1]  C. Smales,et al.  Host cell protein dynamics in the supernatant of a mAb producing CHO cell line , 2012, Biotechnology and bioengineering.

[2]  Pauline M Rudd,et al.  Multiplexed analytical glycomics: rapid and confident IgG N-glycan structural elucidation. , 2011, Journal of proteome research.

[3]  Ryan Nolan,et al.  Dynamic model of CHO cell metabolism. , 2011, Metabolic engineering.

[4]  Sharon F Terry,et al.  An End to the Myth: There Is No Drug Development Pipeline , 2013, Science Translational Medicine.

[5]  Kamil Erguler,et al.  A mathematical model of the unfolded protein stress response reveals the decision mechanism for recovery, adaptation and apoptosis , 2013, BMC Systems Biology.

[6]  D. Pincus,et al.  BiP Binding to the ER-Stress Sensor Ire1 Tunes the Homeostatic Behavior of the Unfolded Protein Response , 2010, PLoS biology.

[7]  E. Angov.  Codon usage: Nature's roadmap to expression and folding of proteins , 2011, Biotechnology journal.

[8]  Joel Lexchin,et al.  The cost of drug development: a systematic review. , 2011, Health policy.

[9]  Bernhardt L Trout,et al.  Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. , 2011, Journal of pharmaceutical sciences.

[10]  Niki S. C. Wong,et al.  Combined in silico modeling and metabolomics analysis to characterize fed‐batch CHO cell culture , 2012, Biotechnology and bioengineering.

[11]  D. Ron,et al.  Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress , 2011, Nature Cell Biology.

[12]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2011 to 2012 , 2012, Nature Biotechnology.

[13]  Bernhardt L Trout,et al.  Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.

[14]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[15]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[16]  S. Sørensen,et al.  Experimental methods and modeling techniques for description of cell population heterogeneity. , 2011, Biotechnology Advances.

[17]  Alain Van Dorsselaer,et al.  Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.

[18]  C. Kontoravdi,et al.  Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  Alfonso Jaramillo,et al.  Empirical model and in vivo characterization of the bacterial response to synthetic gene expression show that ribosome allocation limits growth rate. , 2011, Biotechnology journal.

[20]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.

[21]  Brian Glennon,et al.  Process model comparison and transferability across bioreactor scales and modes of operation for a mammalian cell bioprocess , 2013, Biotechnology progress.

[22]  Alex Xenopoulos,et al.  Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry , 2012, mAbs.

[23]  Michele Vendruscolo,et al.  Prediction of variable translation rate effects on cotranslational protein folding , 2012, Nature Communications.

[24]  K. Polizzi,et al.  In Situ Monitoring of Intracellular Glucose and Glutamine in CHO Cell Culture , 2012, PloS one.

[25]  David B Volkin,et al.  Analytical lessons learned from selected therapeutic protein drug comparability studies. , 2013, Biologicals : journal of the International Association of Biological Standardization.

[26]  C. Herwig,et al.  Efficient feeding profile optimization for recombinant protein production using physiological information , 2012, Bioprocess and Biosystems Engineering.

[27]  M. Vendruscolo,et al.  The Zyggregator method for predicting protein aggregation propensities. , 2008, Chemical Society reviews.

[28]  R. Vabulas,et al.  Protein folding in the cytoplasm and the heat shock response. , 2010, Cold Spring Harbor perspectives in biology.

[29]  L. Gierasch,et al.  FoldEco: a model for proteostasis in E. coli. , 2012, Cell reports.

[30]  C. Kontoravdi,et al.  A dynamic mathematical model for monoclonal antibody N‐linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus , 2011, Biotechnology progress.

[31]  Mark Kessel,et al.  The problems with today's pharmaceutical business—an outsider's view , 2011, Nature Biotechnology.

[32]  A. Demain,et al.  Production of recombinant proteins by microbes and higher organisms. , 2009, Biotechnology advances.

[33]  Yuexin Li,et al.  Quinolone-3-Diarylethers: A New Class of Antimalarial Drug , 2013, Science Translational Medicine.

[34]  Christoph Herwig,et al.  Model-Based Analysis on the Extractability of Information from Data in Dynamic Fed-Batch Experiments , 2013, Biotechnology progress.

[35]  Matthew S. Sachs,et al.  Non-optimal codon usage affects expression, structure and function of FRQ clock protein , 2013, Nature.

[36]  Sandeep Kumar,et al.  Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions , 2011, Pharmaceutical Research.

[37]  S. Cavagnero,et al.  Protein folding rates and thermodynamic stability are key determinants for interaction with the Hsp70 chaperone system , 2012, Protein science : a publication of the Protein Society.

[38]  Vassily Hatzimanikatis,et al.  A computational framework for the design of optimal protein synthesis , 2012, Biotechnology and bioengineering.

[39]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[40]  Bernhardt L Trout,et al.  Prediction of aggregation prone regions of therapeutic proteins. , 2010, The journal of physical chemistry. B.